Reuters logo
India's Sun Pharma Q3 profit falls nearly 5 pct; below estimates
February 14, 2017 / 10:43 AM / 9 months ago

India's Sun Pharma Q3 profit falls nearly 5 pct; below estimates

MUMBAI, Feb 14 (Reuters) - India’s largest drugmaker Sun Pharmaceutical Industries Ltd’s third-quarter profit fell below analysts’ estimates due to slower sales in the United States, its largest market.

Sun’s net profit for the October-December period fell to 14.72 billion rupees ($219.87 million) from 15.45 billion rupees a year earlier. Analysts on average expected a profit of 17.83 billion rupees, according to Thomson Reuters I/B/E/S.

Sun said quarterly U.S. sales rose 4 percent over the year earlier. The company’s U.S. subsidiary Taro Pharmaceutical Industries Ltd last week reported third-quarter sales down 15 percent over the last year. ($1 = 66.9500 Indian rupees) (Reporting by Zeba Siddiqui in Mumbai; Editing by Himani Sarkar and Vyas Mohan)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below